This antigen-antibody reaction inactivates receptor tyrosine kinases (RTKs) activation in various cancer cells A549 (lung cancer), MDA-MB-231 (breast adenocarcinoma, triple negative), MCF7 (primary breast adenocarcinoma) and HeLa (cervical carcinoma) in vitro and preventing even angiogenesis resulting in decreased tumorigenesis in vivo [145]. The gene discussed is NTRK1; the disease is breast adenocarcinoma.